for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Applied Therapeutics Inc

APLT.OQ

Latest Trade

25.80USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

8.50

 - 

57.17

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
25.80
Open
--
Volume
--
3M AVG Volume
5.19
Today's High
--
Today's Low
--
52 Week High
57.17
52 Week Low
8.50
Shares Out (MIL)
21.97
Market Cap (MIL)
566.83
Forward P/E
-8.77
Dividend (Yield %)
--

Latest Developments

More

Applied Therapeutics Announces Appointment Of Chuck Silberstein As Chief Financial Officer And Head Of Business Development

Applied Therapeutics Files Prospectus Supplement Related To Offering Of 1.4 Mln Shares Of Common Stock By Selling Stockholders

Applied Therapeutics Reports First Quarter 2020 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Applied Therapeutics Inc

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). It is also developing AT-001 for diabetic peripheral neuropathy (DPN), a debilitating neurodegenerative disease.

Industry

Biotechnology & Drugs

Contact Info

545 5TH AVENUE, SUITE 1400

NEW YORK, NY

10017

United States

+1.212.2209319

http://www.appliedtherapeutics.com/

Key Stats

1.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-3.550

2020(E)

-2.940
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-58.53
Return on Equity (TTM)
-53.79

Latest News

Latest News

BRIEF-Applied Therapeutics Announces Start Of At-007 Pediatric Galactosemia Study

* APPLIED THERAPEUTICS ANNOUNCES START OF AT-007 PEDIATRIC GALACTOSEMIA STUDY; RELEASES ADDITIONAL 40MG/KG DATA FROM ADULT GALACTOSEMIA STUDY

BRIEF-Applied Therapeutics Files For Mixed Shelf Of Upto $300 Mln

* APPLIED THERAPEUTICS, INC FILES FOR MIXED SHELF OF UPTO $300 MILLION - SEC FILING Source text: (https://bit.ly/2ABQq2l) Further company coverage:

BRIEF-Applied Therapeutics Announces Appointment Of Chuck Silberstein As Chief Financial Officer And Head Of Business Development

* APPLIED THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. CHUCK SILBERSTEIN, MD, MBA, CFA AS CHIEF FINANCIAL OFFICER AND HEAD OF BUSINESS DEVELOPMENT

BRIEF-Applied Therapeutics Files Prospectus Supplement Related To Offering Of 1.4 Mln Shares Of Common Stock By Selling Stockholders

* APPLIED THERAPEUTICS INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF 1.4 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS Source: https://bit.ly/2WjlpbM Further company coverage:

BRIEF-Applied Therapeutics Reports First Quarter 2020 Financial Results

* APPLIED THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Applied Therapeutics Says As Of Now, Co Has Not Experienced Any Significant Delays To Ongoing Or Planned Clinical Trials

* APPLIED THERAPEUTICS - AS OF NOW, CO HAS NOT EXPERIENCED ANY SIGNIFICANT DELAYS TO ITS ONGOING OR PLANNED CLINICAL TRIALS Source: https://bit.ly/2Kjaus1 Further company coverage:

BRIEF-Applied Therapeutics Announces Full Data And Scientific Presentations From The Pivotal Phase 2 Action-Galactosemia Trial

* APPLIED THERAPEUTICS ANNOUNCES FULL DATA AND SCIENTIFIC PRESENTATIONS FROM THE PIVOTAL PHASE 2 ACTION-GALACTOSEMIA TRIAL

BRIEF-Applied Therapeutics Says Hospitals In New York City Have Commenced Investigator-Initiated Studies

* APPLIED THERAPEUTICS ANNOUNCES IND AND INVESTIGATOR-INITIATED STUDIES OF AT-001 IN CRITICAL COVID-19 PATIENTS

IFR US ECM WEEKLY WRAP-UP

WEEKLY TOTAL $4.58bn – IPO $800m – ABB/BLOCK $782m – FOLLOW-ON $2.45bn – CB $550m TUESDAY

IFR US ECM Calendar

Adaptive Biotechnologies (US, biotech) – $212.0m FO. 8m shares (100% sec) at $26.50 versus $26.85 last sale and $26.80 launch. JPM, GS, BOFA.

IFR US ECM Calendar

Adaptive Biotechnologies (US, biotech) – $212.0m FO. 8m shares (100% sec) at $26.50 versus $26.85 last sale and $26.80 launch. JPM, GS, BOFA.

IFR US ECM Calendar

Ares Commercial Real Estate (US, mortgage REIT) – $64.4m Block. 4m shares (100% prim) at $16.09 versus $16.09-$16.38 marketing and $16.54 last sale. WF, CITI, MS.

UPDATE 1-IFR US ECM Calendar

Adaptimmune Therapeutics (UK, biotech) – $84m ABB. 21m shares at (100% prim) $4.00 versus $4.14 last sale. COWN. Upsized from $75m.

IFR US ECM Calendar

Adaptimmune Therapeutics (UK, biotech) – $84m ABB. 21m shares at (100% prim) $4.00 versus $4.14 last sale. COWN. Upsized from $75m.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up